Gallimycin®-36 — veterinary medication

Overview

Source: Animal Drugs @ FDA

Proprietary name

Gallimycin®-36

Active ingredient

Erythromycin

Application type

NADA

Sponsor

Bimeda Animal Health Ltd.

Applications on record

1

First published

March 9, 2023

Adverse event reports

Source: openFDA VeDDRA

87

Reports mentioning this ingredient

April 20, 1987 – December 4, 2025

30

Classified serious

per reporter assessment

15

Lack of expected efficacy

resistance signal

2

Human operator exposure

needle-stick or splash

Not a risk measure. Veterinary adverse event reports are influenced by how many animals are treated, reporting practice and product age. Reports do not establish that the product caused the event, and a single report can cover an entire herd or flock. Attribution here is by active ingredient because the source dataset redacts brand names.

Attributed by active ingredient “ERYTHROMYCIN”. Green Book ingredient names and VeDDRA ingredient names do not always agree exactly, so attribution is approximate and labelled as such.

Reported reactions

Source: openFDA VeDDRA

Clinical signs coded in the VICH VeDDRA four-level hierarchy, most frequent first.

Reaction terms reported for this ingredient, by report count.
Reaction (VeDDRA term)	Reports	Relative frequency
Death	6
Product syringe issue	6
Tubes, Leaking	6
Product Defect, General	5
Mammary gland disorder NOS	4
Potency, Low	4
Seal, Abnormal	3
Blepharospasm	3
Residues in milk	2
Abortion	2
Pain NOS	2
Aggression	2
Erythema (for urticaria see Immune SOC)	2
Lack of efficacy - NOS	2
Injection site swelling	1
Dyspnoea	1
Fever	1
Collapse (see also 'Cardio-vascular' and 'Systemic disorders')	1
Restlessness	1
Injection site reaction NOS	1

Species affected

Source: openFDA VeDDRA

Cat 36 Dog 18 Cattle 14 Human 4 Horse 1 Pig 1

Regulatory context

New Animal Drug Application (NADA). A pioneer approval evaluated for target animal safety, therapeutic effectiveness, manufacturing controls and — for food-producing species — human food safety including residue depletion.

Extra-label use in food-producing animals is governed by the Animal Medicinal Drug Use Clarification Act of 1994 (AMDUCA) and 21 CFR Part 530. It requires a valid veterinarian-client-patient relationship and is prohibited outright for certain drug classes. Withdrawal times are determined by FARAD, not by this index.

Sources for this page

Animal Drugs @ FDA	FDA CVM	Applications, sponsor, status, withdrawal
Animal & Veterinary Events	FDA CVM	VeDDRA adverse event aggregates by active ingredient